Where are we going « wrong »? Lack of coordination between the disciplines  Implication for the Patient – Not informed on the next steps – Not informed.

Slides:



Advertisements
Similar presentations
CHILD HEALTH NURSING.
Advertisements

FROM EUROCHIP-1 TO EUROCHIP-2 EUROCHIP-2 - The action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
Week 5- The Organisation of Health Services Part 2.
Portugal Economic Evaluation Applied to Decision Making Isaura Vieira INFARMED, I.P. – National Authority for Medicines and Health Products I Pan-American.
Improving Cancer Outcomes at a national level - The story from England Professor Sir Mike Richards National Cancer Director June
Prostate Cancer Support Federation Charity Nº: We have no national screening programme for the most common cancer in men and the only test we.
The Global Burden of Hepatitis C Dr Daniel Lavanchy World Health Organization (WHO) Geneva, Switzerland 3 rd Paris Hepatitis Conference.
THE EUROCHIP PROJECTS Health Indicators for Health Indicators for Monitoring Cancer in Europe
Health Care Industry Medical-industrial complex The industry that supplies healthcare for a profit Response to the opportunity to make large profits from.
Copyright 2012 Delmar, a part of Cengage Learning. All Rights Reserved. Chapter 15 Globalization and Health: The World is Flattening.
Cancer Program Standards 2012: Ensuring Patient-Centered Care
DEVELOPMENT AND IMPLEMENTATION OF A LUNG NODULE PROGRAM Tamra Kelly, BS RRT-NPS, Gary B. Mertens, RCP, CPFT, Jenifer Beasley, RRT, Departments of Cancer.
Getting involved in Global Health Dr Rhona MacDonald The Lancet.
EUROCHIP-3 Cancer Health Information Project DG SANCO EC Health Programmes from local actions to common actions: the EU pillars of EU cancer control for.
Healthcare in the UK Margaret Costello – Gorlin Syndrome Group.
Mary S. McCabe Survivorship Care Planning. National Directions Focus on recurrence Increasing expectations by patients and families Identification of.
1 What is Hospice Palliative Care? The Canadian Hospice Palliative Care Association defines hospice palliative care as a special kind of health care for.
Dementia in People with a Learning Disability A Care Pathway Using a Collaborative Approach ANDREW GRIFFITHS.
Achieving improved cancer outcomes- a pathway approach, engaging primary care and partners Kathy Elliott Programme Director – NHS Improving Quality (Delivery.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
HUMAN ENVIRONMENTS REVISION. REVISION STRUCTURE OVER THE NEXT TWO WEEKS WE WILL BE REVISING THE HUMAN ENVIRONMENTS UNIT. THIS WILL BE DONE BY MATCHING.
ADAMOS ADAMOU, MEDICAL ONCOLOGIST MEMBER OF THE EUROPEAN PARLIAMENT.
Danish Health and Medicines Authority  Denmark Dr. Else Smith, CEO Danish Health and Medicines Authority Meeting of the EU Chief Medical Officers, Chief.
Community Oncology Conference Thursday April 23 rd, 2015.
Chapter 14 Health, Health Care, and Disability
DON’T FORGET THE ‘E’ IN “MORPHINE” International Pain Policy Fellowship: Advocacy & Communications.
Heart Failure Programs Europe and Belgium Sandra Martin Clinical Nurse Specialist UZ Leuven, Belgium.
Health Care Reform April 28 & 29, 2010 Jack A. Lenhart, M.D. Medical Director, Valley Preferred Jack A. Lenhart, M.D. Medical Director, Valley Preferred.
INSURANCE & COSTS HEALTH CARE SERVICES. MEDICAL CARE (INSURANCE) HEALTH MAINTANCE ORGANIZATION (HMO) – A TYPE OF GROUP HEALTH INSURANCE PLAN – MEDICAL.
European Society of Cardiology Cardiovascular diseases in women.
Organization of pediatrics in the Netherlands History Organization of pediatric care Quality Pediatric training Financing and income Role of pediatricians.
JCUH NICE MSCC Guidelines Compliance audit Ruth Mhlanga Senior Specialist Physiotherapist Oncology and Haematology.
1 Cost-Sharing: Effects on Spending and Outcomes Briefing by Katherine Swartz, PhD Harvard School of Public Health February 3, 2011.
In 2003, Medicaid spent $33.7 billion on drugs (19% of national spending for drugs and more than 10% of the Medicaid budget) Medicaid expenditures ($ billions)
Assoc Prof Dr Mohd Idzwan bin Zakaria
Gérard Vincent/FHF1 INTERNATIONAL HOSPITAL FEDERATION 32nd Congress HONG KONG 15 – 18 May 2001.
Occupational Health. Occupational Medicine Recognized Specialty Since 1949 Combines Clinical Skills With Toxicology, Epidemiology, Safety, Rehabilitation,
Capacity for Consent - How Much Do We Know About It? Kate Evans Specialist Registrar in Emergency Medicine Derriford Hospital, Plymouth.
Neurologist Dr. Antanas Vaitkus The Migraine management in Lithuania.
Dr Shanthi Pal Quality Assurance and Safety of Medicines WHO
WHAT DOES MEDICAL HOME MEAN TO YOUR FAMILIES. Medical Care is just part of our lives.
Definition of Family Medicine General practice / Family Medicine is an academic and scientific discipline, has its own educational content, research, evidence.
Linda Devereux Associate Director Merseyside and Cheshire Cancer Network - why we are here and what’s next!
The Migraine Awareness Maria-Magdalena WYSOCKA-BAKOWSKA.
Reform through Objectives Reform in the Healthcare System.
Chronic diseases as tracer conditions in international benchmarking of health systems: the example of diabetes 1 European Centre on Health of Societies.
“Measuring the Units” Alcohol liaison services (ALS) Louise Poley Consultant Nurse in Substance Misuse Cardiff and Vale University Health Board.
Jan 2002 EDMA The central role of the Medical Laboratory in a World of Managed Health An EDMA presentation of the benefits of in vitro testing as a basis.
The profession of a DOCTOR
Learning from patients’ experience Angela Coulter Picker Institute Europe Angela Coulter Picker Institute Europe
ICIUM Working Together for Mental Health: the Nouadhibou Pilot Experience D. Gérard, A. Ould Hamady, R. Sebbag, F. Bompart ICIUM 2011, Antalya,
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
Professor Orla Hardiman HRB Clinician Scientist Innovation Its role in Delivering Better Health Outcomes.
Health Insurance. Purpose of Health Insurance  To aid individuals and families in living healthier lives, provide basic medical services and protect.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC™-O Curriculum is produced by the EPEC TM Project with major funding.
Ireland Niamh Rice IrSPEN Warsaw 20 th May Optimal nutritional care for all Education Public health Implementation Undergrad Postgrad Nutrition.
Bengt Jönsson, Professor emeritus Stockholm School of Economics
2 November John Childs and Deborah Woodley
Thomas F. Babor, Ph.D., MPH Dennis McCarty, Ph.D.
WHAT DOES A BIOMEDICAL TECHNICIAN DO?
Clinical evaluation of UHC for cancer
Primary Care in the Czech Republic
Unveil the importance of pain management in cancer patients
AN OVERVIEW OF THE BONE METASTASES PROGRAM
Tit Albreht | Brussels | 7 November 2017
AIDS TO A HIGH CATARACT SURGICAL RATE
MULTIDISCIPLINARY (MDT) APPROACH TO CLINICAL CARE MODEL FOR EFFECTIVE AND BEST EVIDENCE PATIENT CARE DR EZEKIEL ALAWALE MBBS, FWACS, FRCS(I), JCPTGP, GP.
Thank you for viewing this presentation.
Presentation transcript:

Where are we going « wrong »? Lack of coordination between the disciplines  Implication for the Patient – Not informed on the next steps – Not informed on when where and what by whom (loss of autonomy) – No guidelines publically available BUT does the medical training focus on coordination or on being good in its profession??? Are the medical specialist well trained?? Huge difference over Europe!

Where are we going « wrong »? Availability of guidelines on diagnosis and treatment BUT are these evidence based? If so why are they different between regions or countries?? And what is evidence –based? what is the right treatment? Personlised medicine GLs:Not applicable to all patients (how to explain this to patients but also to insurance companies)

Where are we going « wrong »? Depending on the GDP or NHE more or less high tech equipments available: MRI,PET scans, radiotherapy….but usually very expensive drugs are available in poor countries!!! Role (lobby) of pharmaceutical industries

EUROCARE-4 5-year relative survival, all cancers countries are orded by Total Expenditure on Healh Europe Berrino F. et al, The Lancet Oncology, 2007

Where are we going « wrong »? What is a dedicated team? Or what is a « good » hospital?? How to measure this? Volume per specialist ??? Volume per hospital?? NO: but volume per team But how to deal with this in a poor country with only a few inh/km 2 ?

Model for comprehensive oncological pathway

Where are we going « wrong »? Starting a population-based screening programme (political decision) – without any possibility to treat the referred patient adequatly (no specialized surgeon, no radiotherapy equipment…) – Without any possibility of evaluation of the effect of the screening (no monitor instrument as a CR including stage)

Where are we going « wrong »? More survivors due to better survival:  new « problem »: Rehabilitation into the society Back to work Who can give this kind of support to the patients? Who is paying for this?

Where are we going « wrong »? Antismoking campaigns? Not succesful because of the lobby of the tobacco industry: political issue!!! Health is less important than the economy: « the cheapest patient is the one who dies very fast, and never reaches his retirement »

In conclusion We miss the comprehensive approach (NCCP) We forget to consider the patient as a respectful « normal » person We always blame the doctors but they work within the health care system as build in their country We are still dealing with what is GOOD as we re not aware of all the factors responsible for GOOD outcome we still miss very important information on cancer care indicators

Growth of cancer

Histologie